Abstract:Summary Statement Combination of sorafenib with irradiation achieved synergistic effect with dose reduction in both 143B and HOS cell lines. This demonstrated the potential application of sorafenib in the treatment of osteosarcoma metastasis and radiation resistance. Introduction More than 20% of patients with osteosarcoma die of the disease within 5 years due to tumour relapse and metastasis. Identifying new treatment that works singly or in combination with conventional therapies is urgently required. We previously found that the Ras/Raf/MAPK pathway was associated with lung metastasis in a 143B inoculated osteosarcoma orthotopic mouse model 1 . Sorafenib, a multi-kinase inhibitor, has shown potent anticancer effect including in osteosarcoma 2 through the inhibition of Raf-1 and other targets 3 . The aims of this study were to investigate effect of sorafenib on osteosarcoma cell lines with or without activated Ras/Raf/MAPK signalling and to decide whether sorafenib could enhance irradiation on these cells. Materials and Methods Osteosarcoma cell lines 143B (HOS with Ras gene transfection), HOS and U2OS were used. Clonogenic assay was applied for assessing tumour growth and colony formation with or without treatment. Sorefenib was provided by Bayer gratis. Irradiation was performed using the Therapax DXT300 Orthovoltage Radiation System (Pantak, Connecticut, USA). Three doses of sorafenib (1, 2, 4 ug/ml) and three doses of radiation (50, 100, 200 cGy) were used with vehicle controls. In the combination therapy sorafenib was given at pre-, concurrent and post-irradiation. Each treatment was duplicated with the experiment being repeated once. Results Sorafenib monotherapy achieved 50% inhibition (EC50) effects in all three tested cell lines with 7.05 ug/ml for 143B, 1.59 for HOS and 2.41 for U2OS. The 143B cell line was seriously resistant to irradiation with EC50 of 167 Gy, whilst other cell lines were relatively sensitive (HOS, 1.5 Gy and U2OS, 1.0 Gy). Combination of sorafenib with irradiation achieved synergistic effect with dose reduction in both 143B and HOS cell lines, but no obvious effect in U2OS cells. Discussion Sorafenib demonstrated inhibitory effects on cell growth and colony formation even in a Ras/Raf/MAPK signalling activated osteosarcoma cell line, suggesting its potential application in the treatment of some metastatic osteosarcoma. Activated Ras/Raf/MAPK signalling is one of the mechanisms of radiation resistance and the synergistic effect of soratenib with irradiation combination therapy in this cell population indicated it9s potential application in the treatment of irradiation resistant osteosarcoma. The dose reduction achieved by this combination could benefit patients with less specific side effects.

Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo.

Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner

Sorafenib Decreases the Anti-tumor Effect of Radiation in Hepatocelluar Carcinoma in vitro

Advantage of Sorafenib Combined with Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma

Schedule-dependant in Vitro Anti-tumor Effect of Radiation Combined with Sorafenib in Hepatocellular Carcinoma

Sorafenib Suppresses the Rapid Progress of Hepatocellular Carcinoma after Insufficient Radiofrequency Ablation Therapy: an Experiment in Vivo

Inhibition of the Wnt/β-catenin Signaling Pathway Improves the Anti-Tumor Effects of Sorafenib Against Hepatocellular Carcinoma.

Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study

Improved Antitumor Effect Of Combining Wnt/Beta-Catenin Inhibition With Sorafenib In Hepatocellular Carcinoma

Sorafenib Enhances the Chemotherapeutic Efficacy of S-1 Against Hepatocellular Carcinoma Through Downregulation of Transcription Factor E2F-1

Sorafenib In Advanced Hepatocellular Carcinoma: Current Status And Future Perspectives

SORAFENIB MONOTHERAPY AND COMBINATION THERAPY WITH IRRADIATION IN OSTEOSARCOMA CELL LINES

Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant hep G2 cells through a mitochondria-dependent oxidative stress mechanism

The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma

Sorafenib Blocks the Activation of the HIF-2α/VEGFA/EphA2 Pathway, and Inhibits the Rapid Growth of Residual Liver Cancer Following High-Intensity Focused Ultrasound Therapy in Vivo.

Effect of the Combination Therapy of Sorafenib and Radiofrequency Ablation on the Survival Time of Advanced Hcc.

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

Sorafenib May Enhance Antitumour Efficacy in Hepatocellular Carcinoma Patients by Modulating the Proportions and Functions of Natural Killer Cells.

Sorafenib-Conjugated Zinc Phthalocyanine-Based Nanocapsule for Trimodal Therapy in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.

Robust Combination of Liver Stereotactic Body Radiotherapy Modulates Pharmacokinetics of Sorafenib Toward Preferable Parameters.

Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity